Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10292761" target="_blank" >RIV/00064203:_____/14:10292761 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/14:10292761

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.eururo.2013.08.034" target="_blank" >http://dx.doi.org/10.1016/j.eururo.2013.08.034</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.eururo.2013.08.034" target="_blank" >10.1016/j.eururo.2013.08.034</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder

Popis výsledku v původním jazyce

Background: Few studies have investigated the natural history of TaG1 urothelial carcinoma of the bladder (UCB). Objective: To assess the long-term outcomes of patients with TaG1 UCB and the impact of immediate postoperative instillation of chemotherapy(IPIC). Design, setting, and participants: A retrospective analysis of 1447 patients with TaG1 UCB treated between 1996 and 2007 at eight centers. Median follow-up was 67.2 mo (interquartile range: 67.9). Patients were stratified into three European Association of Urology (EAU) guidelines risk categories; high-risk patients (n = 11) were excluded. Intervention: Transurethral resection of the bladder with or without IPIC. Outcome measurements and statistical analysis: Univariable and multivariable Cox regression models addressed factors associated with disease recurrence, disease progression, death of disease, and any-cause death. Results and limitations: Of the 1436 patients, 601 (41.9%) and 835 (58.1%) were assigned to low-and intermed

Název v anglickém jazyce

Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder

Popis výsledku anglicky

Background: Few studies have investigated the natural history of TaG1 urothelial carcinoma of the bladder (UCB). Objective: To assess the long-term outcomes of patients with TaG1 UCB and the impact of immediate postoperative instillation of chemotherapy(IPIC). Design, setting, and participants: A retrospective analysis of 1447 patients with TaG1 UCB treated between 1996 and 2007 at eight centers. Median follow-up was 67.2 mo (interquartile range: 67.9). Patients were stratified into three European Association of Urology (EAU) guidelines risk categories; high-risk patients (n = 11) were excluded. Intervention: Transurethral resection of the bladder with or without IPIC. Outcome measurements and statistical analysis: Univariable and multivariable Cox regression models addressed factors associated with disease recurrence, disease progression, death of disease, and any-cause death. Results and limitations: Of the 1436 patients, 601 (41.9%) and 835 (58.1%) were assigned to low-and intermed

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Urology

ISSN

0302-2838

e-ISSN

—

Svazek periodika

65

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

9

Strana od-do

201-209

Kód UT WoS článku

000327766500037

EID výsledku v databázi Scopus

—